valproic acid has been researched along with Acute Promyelocytic Leukemia in 10 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of all-trans retinoic acid (ATRA) and valproic acid (VPA), alone and in combination, on the human acute promyelocytic leukemia (APL) cell line NB4 were investigated in view of differentiation induction and growth inhibition." | 3.80 | Enhancement of differentiation induction and upregulation of CCAAT/enhancer-binding proteins and PU.1 in NB4 cells treated with combination of ATRA and valproic acid. ( Aizawa, S; Hatta, Y; Horikoshi, A; Iriyama, N; Takagi, N; Takei, M; Takeuchi, J; Toyoda, H; Yoshino, Y; Yuan, B, 2014) |
| " Multiplexing mAbs against CD11b and CD11c provided surrogate imaging biomarkers of differentiation therapy in an acute promyelocytic leukemia model treated with all-trans retinoic acid combined with the histone-deacetylase inhibitor valproic acid." | 3.79 | Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. ( Bruserud, Ø; Gjertsen, BT; McCormack, E; Mujić, M; Osdal, T, 2013) |
| " We have used several models of PML-RARA-driven acute promyelocytic leukemias (APLs) to analyze the in vivo effects of valproic acid, a well-characterized HDACis." | 3.78 | Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. ( Dal Zuffo, R; de Thé, H; Leiva, M; Mercurio, C; Minucci, S; Moretti, S; Pallavicini, I; Peres, L; Soilihi, H, 2012) |
| "We exploited murine models of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia driven by the promyelocytic leukemia/retinoic acid receptor (PML-RARα) oncofusion protein, which recruits histone deacetylase (HDAC)-containing complexes." | 1.72 | Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication. ( Abdel-Aziz, AK; Ceccacci, E; de Thé, H; Minucci, S; Moretti, S; Pallavicini, I; Santoro, F, 2022) |
| "Valproic acid (VPA) is a broad-spectrum inhibitor of histone deacetylase, which has been used in cancer therapy." | 1.36 | Curcumin p38-dependently enhances the anticancer activity of valproic acid in human leukemia cells. ( Chen, J; Kang, J; Wang, G; Wang, J; Wang, L, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moretti, S | 3 |
| Abdel-Aziz, AK | 1 |
| Ceccacci, E | 1 |
| Pallavicini, I | 3 |
| Santoro, F | 2 |
| de Thé, H | 2 |
| Minucci, S | 3 |
| Botrugno, OA | 1 |
| Dal Zuffo, R | 2 |
| Matthews, GM | 1 |
| Cluse, L | 1 |
| Barozzi, I | 1 |
| Senese, S | 1 |
| Fornasari, L | 1 |
| Altucci, L | 1 |
| Pelicci, PG | 1 |
| Chiocca, S | 1 |
| Johnstone, RW | 1 |
| Iriyama, N | 1 |
| Yuan, B | 1 |
| Yoshino, Y | 1 |
| Hatta, Y | 1 |
| Horikoshi, A | 1 |
| Aizawa, S | 1 |
| Takei, M | 1 |
| Takeuchi, J | 1 |
| Takagi, N | 1 |
| Toyoda, H | 1 |
| Rezacova, M | 1 |
| Zaskodova, D | 1 |
| Vavrova, J | 1 |
| Vokurkova, D | 1 |
| Tichy, A | 1 |
| St-Germain, JR | 1 |
| Chen, J | 2 |
| Li, Q | 1 |
| Wang, G | 1 |
| Wang, L | 1 |
| Kang, J | 1 |
| Wang, J | 1 |
| Leiva, M | 1 |
| Soilihi, H | 1 |
| Peres, L | 1 |
| Mercurio, C | 1 |
| Ivanova, D | 1 |
| Gronemeyer, H | 1 |
| Steinberg, P | 1 |
| Nau, H | 1 |
| McCormack, E | 1 |
| Mujić, M | 1 |
| Osdal, T | 1 |
| Bruserud, Ø | 1 |
| Gjertsen, BT | 1 |
| McMullin, MF | 1 |
| Nugent, E | 1 |
| Thompson, A | 1 |
| Hull, D | 1 |
| Jones, FG | 1 |
| Grimwade, D | 1 |
10 other studies available for valproic acid and Acute Promyelocytic Leukemia
| Article | Year |
|---|---|
Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication.
Topics: Animals; Antineoplastic Agents; Cell Differentiation; Disease Eradication; Histone Deacetylase Inhib | 2022 |
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance.
Topics: Animals; Blotting, Western; Cell Differentiation; Cell Proliferation; Cell Transformation, Neoplasti | 2013 |
Enhancement of differentiation induction and upregulation of CCAAT/enhancer-binding proteins and PU.1 in NB4 cells treated with combination of ATRA and valproic acid.
Topics: Antineoplastic Agents; CCAAT-Enhancer-Binding Protein-alpha; CCAAT-Enhancer-Binding Protein-beta; CC | 2014 |
Antileukemic activity of the combination of ionizing radiation with valproic acid in promyelocytic leukemia cells HL-60.
Topics: Acetylation; Apoptosis; Cell Cycle; Cell Proliferation; Combined Modality Therapy; Histones; HL-60 C | 2008 |
Involvement of PML nuclear bodies in CBP degradation through the ubiquitin-proteasome pathway.
Topics: Cell Line, Tumor; CREB-Binding Protein; E1A-Associated p300 Protein; Fluorescent Antibody Technique; | 2008 |
Curcumin p38-dependently enhances the anticancer activity of valproic acid in human leukemia cells.
Topics: Acetylation; Antineoplastic Agents; Base Sequence; Chromatin Immunoprecipitation; Curcumin; DNA Prim | 2010 |
Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.
Topics: Acetylation; Animals; Anticonvulsants; Antineoplastic Agents; Cell Differentiation; Cell Transformat | 2012 |
Enantioselective apoptosis induction in histiocytic lymphoma cells and acute promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Flow Cytometry; Histone Deacetylase Inhibitors | 2013 |
Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD1 | 2013 |
Prolonged molecular remission in PML-RARalpha-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sc | 2005 |